Author

J. R. Slupsky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A. D. Duckworth· 2 shared J. F. Woolley· 2 shared A. Alshayeb· 1 shared A. F. Khan· 1 shared A. Holroyd· 1 shared A. M. Michie· 1 shared A. Tarafdar· 1 shared B. H. Lloyd· 1 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. D. Duckworth

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity

P. T. Kennedy, E. L. Saulters, A. D. Duckworth, Y. J. Lim, J. F. Woolley, J. R. Slupsky, M. S. Cragg, F. J. Ward, L. N. Dahal

This study shows that soluble CTLA-4 suppresses T-cell activation and promotes tumor growth in mice, and that blocking sCTLA-4 enhances anti-tumor immunity.

bioRxiv · Jun 5, 2023 · PreprintCancer Biology

PKCβ facilitates leukemogenesis in chronic lymphocytic leukaemia by promoting constitutive BCR-mediated signaling

J. Hay, A. Tarafdar, A. Holroyd, H. A. Moka, K. M. Dunn, A. Alshayeb, B. H. Lloyd, J. Cassels, N. Malik, A. F. Khan, I. Sou, J. Lees, H. N. Almuhanna, N. Kalakonda, J. R. Slupsky, A. M. Michie

This study shows PKCβ promotes CLL by enhancing BCR signaling and identifies SP1 as a regulator of PKCβ expression in leukemogenesis.

bioRxiv · Sep 4, 2022 · PreprintCancer Biology

Development of a bispecific Antibody Drug Conjugate targeting CD7 and CD33 to treat Acute Myeloid Leukaemia

A. D. Duckworth, C. Eberlein, V. Pollard, R. Bethell, J. R. Slupsky, O. Schon, J. F. Woolley, T. Thorn

This paper develops a bispecific antibody-drug conjugate targeting CD7 and CD33 for AML treatment, showing improved selectivity and safety in preclinical studies.

bioRxiv · Jul 17, 2022 · PreprintCancer Biology